COYA

2.9501.01%
AV

Anabella Villalobos

Independent Director

Dr. Anabella Villalobos, Ph.D., serves as an Independent Director at Coya Therapeutics, Inc. since May 25, 2021. Dr. Villalobos serves as its Chief Scientific Officer at Metaphore Biotechnologies, Inc. from September, 2025. She is to oversee the advancement of MIMIC, the world's first structure-independent sequence-to-function platform for protein design and the company's drug discovery and development efforts. She has drug discovery and development experience. Dr. Villalobos had been Senior Vice President of Biotherapeutic & Medicinal Sciences at Biogen Inc. since July 31, 2017 and served as Head of Biotherapeutics and Medicinal Sciences. Dr. Villalobos joined Biogen from Pfizer Worldwide Research and Development, where she served as Vice President and Head of Medicinal Synthesis Technologies. As a leader, her group at Pfizer was instrumental in the discovery of Ogsiveo (nirogacestat), tavapadon and other first-in-class therapeutics. With industry experience in the areas of neuroscience and medicinal chemistry, she has been instrumental in the development of clinical candidates for Alzheimer’s disease, Parkinson’s disease, schizophrenia and pain. Before joining industry, Dr. Villalobos has also championed new scientific directions that have improved design practices in medicinal chemistry including the Central Nervous System Multi-Parameter Optimization (CNS MPO) design tool and a novel PET ligand design and discovery approach. Dr. Villalobos received a BS in Chemistry from the University of Panama, a Ph.D. in Medicinal Chemistry from The University of Kansas and Synthetic Organic Chemistry Training at Yale University as a National Institutes of Health Postdoctoral Fellow. She was a National Institutes of Health Postdoctoral Fellow at Yale University in synthetic organic chemistry for two years.

Positions